Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19932057 | 1.00 | NR1D1 (0.57) | NR1D1POLBCXCR3BCL2BAD | |
| SCHEMBL19931770 | 0.91 | NR1D1 (0.53) | NR1D1POLBCXCR3BCL2BAD | |
| SCHEMBL19931777 | 0.87 | NR1D1 (0.63) | NR1D1POLBBCL2BADPREP | |
| SCHEMBL19931877 | 0.84 | PREP (0.53) | POLBCXCR3PREPTDP1L3MBTL1 | |
| SCHEMBL19927287 | 0.84 | POLB (0.55) | POLBCXCR3PREPTDP1L3MBTL1 | |
| SCHEMBL19927286 | 0.84 | POLB (0.55) | POLBCXCR3PREPTDP1L3MBTL1 | |
| SCHEMBL30377746 | 0.82 | CXCR3 (0.54) | CXCR3 | |
| SCHEMBL28556786 | 0.81 | NR1D1 (0.68) | NR1D1POLBBCL2BADACE | |
| SCHEMBL29409301 | 0.81 | NR1D1 (0.68) | NR1D1POLBBCL2BADACE | |
| SCHEMBL19931762 | 0.81 | CXCR3 (0.46) | POLBCXCR3PREPTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | NR1D1 517/4885POLB 2573/4885CXCR3 1/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | NR1D1 517/4885POLB 2573/4885CXCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.